Harry Moultrie


List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2261218/harry-moultrie-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.



#	Paper	IF	Citations
64	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study <i>Lancet, The</i> , 2022 ,	40	152
63	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study <i>Lancet, The</i> , 2022 , 399, 1141-1153	40	7
62	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa <i>Science</i> , 2022 , 376, eabn4947	33.3	89
61	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions <i>Lancet Respiratory Medicine,the</i> , 2022 ,	35.1	6
60	Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa New England Journal of Medicine, 2022,	59.2	3
59	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa <i>New England Journal of Medicine</i> , 2021 ,	59.2	132
58	Advancing TB research using digitized programmatic data. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021 , 25, 890-895	2.1	O
57	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. <i>Lancet Infectious Diseases, The</i> , 2021 ,	25.5	7
56	A position statement and practical guide to the use of particulate filtering facepiece respirators (N95, FFP2, or equivalent) for South African health workers exposed to respiratory pathogens including and SARS-CoV-2. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021 , 27,	0.2	1
55	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab040	1	10
54	A geospatial analysis of two-hour surgical access to district hospitals in South Africa. <i>BMC Health Services Research</i> , 2020 , 20, 744	2.9	2
53	Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018 , 22, 1322-1328	2.1	5
52	Alcohol use and sexual risk behaviour among men and women in inner-city Johannesburg, South Africa. <i>BMC Public Health</i> , 2017 , 17, 548	4.1	21
51	Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. <i>PLoS ONE</i> , 2017 , 12, e0186557	3.7	34
50	CHAPAS-3 fills the gap. Lancet Infectious Diseases, The, 2016 , 16, 133-4	25.5	2
49	Correlation of Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in in an HIV/AIDS Endemic Setting, South Africa. <i>Frontiers in Microbiology</i> , 2016 , 7, 1947	5.7	10
48	Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children. <i>Pediatric Pulmonology</i> , 2016 , 51, 157-64	3.5	12

(2013-2015)

47	Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2015 , 34, 175-9	3.4	16
46	Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy: Individual and Population-level References. <i>Pediatric Infectious Disease Journal</i> , 2015 , 34, e254-9	3.4	3
45	Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 543-9	5.1	37
44	Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients. <i>South African Medical Journal</i> , 2015 , 105, 330-1	1.5	2
43	Novel biomarkers for paediatric tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 900-1	25.5	1
42	Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014 , 18, 676-81	2.1	4
41	Focus on adolescents with HIV and AIDS. South African Medical Journal, 2014, 104, 897	1.5	9
40	Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 617-22	3.4	26
39	Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 499-503	3.4	21
38	Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 608-16	3.4	18
37	Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study. <i>Aids</i> , 2014 , 28, 2451-60	3.5	12
36	Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 846-54	3.4	13
35	The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014 , 67, 136-44	3.1	4
34	Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. <i>Tropical Medicine and International Health</i> , 2013 , 18, 194-8	2.3	17
33	Cost and outcomes of paediatric antiretroviral treatment in South Africa. Aids, 2013, 27, 243-50	3.5	22
32	Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 63, 142-5	3.1	16
31	A survey of paediatric HIV programmatic and clinical management practices in Asia and sub-Saharan Africathe International epidemiologic Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2013 , 16, 17998	5.4	32
30	When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. <i>PLoS Medicine</i> , 2013 , 10, e1001555	11.6	27

29	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. <i>Aids</i> , 2013 , 27, 1933-40	3.5	40
28	Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. <i>Aids</i> , 2013 , 27, 781-5	3.5	19
27	Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. <i>Global Health Action</i> , 2013 , 6, 19248	3	26
26	Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA Collaboration. <i>PLoS ONE</i> , 2013 , 8, e81037	3.7	28
25	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. <i>Tropical Medicine and International Health</i> , 2012 , 17, 1386-90	2.3	9
24	Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1707-18	11.6	57
23	Short-term risk of anaemia following initiation of combination antiretroviral treatment in HIV-infected patients in countries in sub-Saharan Africa, Asia-Pacific, and central and South America. <i>Journal of the International AIDS Society</i> , 2012 , 15, 5	5.4	28
22	Variability of growth in children starting antiretroviral treatment in southern Africa. <i>Pediatrics</i> , 2012 , 130, e966-77	7.4	38
21	Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. <i>New England Journal of Medicine</i> , 2012 , 366, 2380-9	59.2	155
20	The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 417-25	3.1	100
19	Effect of baseline immune suppression on growth recovery in HIV positive South African children receiving antiretroviral treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 61, 235-42	3.1	10
18	Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 428-37	3.1	107
17	Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 273-7	3.4	20
16	The effect of early initiation of antiretroviral treatment in infants on pediatric AIDS mortality in South Africa: a model-based analysis. <i>Pediatric Infectious Disease Journal</i> , 2012 , 31, 474-80	3.4	41
15	A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. <i>Journal of the International AIDS Society</i> , 2011 , 14, 7	5.4	19
14	Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 974-9	3.4	48
13	Virologic failure and second-line antiretroviral therapy in children in South Africathe IeDEA Southern Africa collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 270-8	3.1	96
12	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa Collaboration. <i>Tropical Medicine and International Health</i> , 2011 , 16, 1367-71	2.3	20

LIST OF PUBLICATIONS

11	Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. <i>PLoS ONE</i> , 2011 , 6, e17273	3.7	34
10	Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 524-32	3.1	76
9	Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. <i>Aids</i> , 2010 , 24, 139-46	3.5	32
8	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. <i>Aids</i> , 2010 , 24, 1341-9	3.5	37
7	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009 , 99, 653-60	1.5	43
6	Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009 , 99, 730-7	1.5	90
5	Protective Effect of HIV-Positive Primary Caregivers on Mortality in Children Receiving Antiretroviral Therapy?. <i>Journal of Infectious Diseases</i> , 2008 , 198, 939-940	7	1
4	Challenges to pediatric HIV care and treatment in South Africa. <i>Journal of Infectious Diseases</i> , 2007 , 196 Suppl 3, S474-81	7	78
3	Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa		15
2	Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa		9
1	Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa		143